作者:泰达国际心血管病医院 郑刚
1.1双联抗血小板治疗后的替卡格雷单药治疗
2.3高出血风险
参考文献
2. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pre treatment with clopidogrel and aspirin followed by long-term therapy in patients under going percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358: 527–33. https://doi.org/10.1016/s0140-6736(01)05701-4
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045–57.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15. https://doi.org/10.1056/NEJMoa0706482
6. Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 2018;15:480–96. https://doi.org/10.1038/s41569-018- 0049-1 7. Armstrong PCJ, Dhanji ARA, Tucker AT, Mitchell JA, Warner TD. Reduction of platelet thromboxane A(2) production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 2010;8:613–5.
8. Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either tica grelor or prasugrel. J Thromb Haemost 2011;9:2103–5.
9. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhib ition of platelet aggregation. J Thromb Haemost 2011;9:552–61.
10. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60. https://doi.org/10.1016/S0140-6736(09)60503-1
11. Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A critical ap praisal of aspirin in secondary prevention: is less more? Circulation 2016;134:1881–906.
12. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after im plantation of a drug- eluting stent: a multicentre, open- label, randomised superiority trial. Lancet 2018;392:940–9. https://doi.org/10.1016/S0140-6736(18)31858-0
13. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug- eluting coronary stent ing. J Am Coll Cardiol 2019;74:2223–34.
14. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:2032–42. https://doi.org/10.1056/NEJMoa1908419
15. Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monother apy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020;323: 2407–16.
16. Hong SJ, Lee SJ, Suh Y, Yun KH, Kang TS, Shin S, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation 2023.
17. Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergo ing percutaneous coronary intervention: the SMART- CHOICE randomized clinical trial. JAMA 2019;321:2428–37. https://doi.org/10.1001/jama.2019.8146
18. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019;321:2414–27.
19. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet ther apy with 12 months of dual antiplatelet therapy in patients with acute coronary syn drome. JAMA Cardiol 2022;7:407–17. https://doi.org/10.1001/jamacardio.2021.5244
20. Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, et al. Extended antiplatelet therapy with clo pidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dua lantiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design ofthe OPT-BIRISK double-blinded, placebo-con trolled randomized trial. Am Heart J 2023;228:1–7.
21. Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, et al. Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoa gulants in patients with atrial fibrillation undergoing percutaneous coronary interven tion: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e017212.
22. Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation 2023.
23. Kogame N, Guimarães PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study. JACC Cardiovasc Interv 2020;13:2251–62.
24. Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al. Prasugrel monotherapy after percutaneous coronary intervention with biodegradable polymer platinum-chromium everolimus eluting stent for Japanese patients with chron ic coronary syndrome (ASET-JAPAN). Circ J 2023;87:857–65. https://doi.org/10.1253/ circj.CJ-23-0051
25. van der Sangen NMR, Claessen BEPM, Küçük IT, den Hartog AW, Baan J, Beijk MAM, et al. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study. EuroIntervention 2023;19:63–72.
26. Lee SY, Jeong YH, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, et al. P2y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study. JACC Cardiovasc Interv 2023;16:1845–55.
27. Yun KH, Cho JY, Lee SY, Rhee SJ, Kim BK, Hong MK, et al. Ischemic and bleeding events of ticagrelor monotherapy in Korean patients with and without diabetes mellitus: in sights from the TICO trial. Front Pharmacol 2021;11:620906.
28. Lee SJ, Cho JY, Kim BK, Yun KH, Suh Y, Cho YH, et al. Ticagrelor monotherapy versus ticagrelor with aspirin in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2021;14:431–40.
29. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes. JAMA Cardiol 2019;4:1092–101. https://doi.org/10.1001/jamacardio.2019.3355
30. Vranckx P, Valgimigli M, Odutayo A, Serruys PW, Hamm C, Steg PG, et al. Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre- specified analysis of the GLOBAL LEADERS trial. J Am Heart Assoc 2021;10:e015560.
31. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 2020;41:3533–45. https://doi.org/10.1093/eurheartj/ehaa670
32. Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, et al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet ther apy in patients who underwent complex percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. Eur Heart J 2019;40:2595–604.
33. Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol 2020;75:2414–24. https://doi.org/10. 1016/j.jacc.2020.03.011
34. Yamamoto K, Watanabe H, Morimoto T, Domei T, Ohya M, Ogita M, et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients who under went complex percutaneous coronary intervention: insight from the STOPDAPT-2 trial. Circ Cardiovasc Interv 2021;14:e010384.
35. Roh JW, Hahn JY, Oh JH, Chun WJ, Park YH, Jang WJ, et al. P2y12 inhibitor monother apy in complex percutaneous coronary intervention: a post-hoc analysis of SMART-CHOICE randomized clinical trial. Cardiol J 2021;28:855–63.
36. Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, et al. P2y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary inter ventions. J Am Coll Cardiol 2023;81:537–52.
37. Nicolas J, Dangas G, Chiarito M, Pivato CA, Spirito A, Cao D, et al. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2023;9:240–50.
38. Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antipla telet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2022;8:28–38. https://doi.org/10.1093/ehjcvp/pvaa106
39. Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J 2021;42:4624–34.
40. Lee YJ, Suh Y, Kim JS, Cho YH, Yun KH, Kim YH, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial. Korean Circ J 2022;52:324–37.
41. Yamamoto K, Watanabe H, Morimoto T, Obayashi Y, Natsuaki M, Domei T, et al. Clopidogrel monotherapy after 1-month DAPT in patients with high bleeding risk or complex PCI. JACC Asia 2023;3:31–46. https://doi.org/10.1016/j.jacasi.2022.09.011 42. Costa F, Montalto C, Branca M, Hong SJ, Watanabe H, Franzone A, et al. Dual antiplate let therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. Eur Heart J 2023;44:954–68.
本文内容为《门诊》杂志原创内容
转载须经授权并请注明出处。
《门诊》杂志官方微信
长按,识别二维码,加关注